Dunn-Edwards Corp. said late Wednesday that it has named Michael Badar president and chief operating officer. The privately held, Los Angeles-based architectural paint manufacturer said Badar is replacing Mike Rose, who was president from 2000 until April. No reason for Rose's departure was given. Founded in 1925, Dunn-Edwards operates more than 95 retail stores in California, Arizona, Nevada, New Mexico and Texas and employs about 1,750.
Cogent Inc. said Thursday that it has withdrawn its patent lawsuit against UPEK Inc. and reached a licensing agreement with the biometrics equipment maker. Pasadena-based Cogent said it reached an agreement that will allow Emeryville-based UPEK to incorporate certain technologies patented by Cogent in its fingerprint biometric sensor products. Financial terms of the deal were not disclosed.
Biotech research and development firm CytRx Corp. said Thursday that the chief financial officer of its RXi Pharmaceuticals subsidiary, James Warren, has left the company to pursue other opportunities. Warren will be replaced by Stephen DiPalma, who co-founded medical company Catalyst Oncology Inc. RXi Pharmaceuticals was started by CytRx in January and focuses solely on RNAi technology, or gene silencing. Shares in CytRx dropped 1.1 percent to $3.30 in afternoon trading Thursday on the Nasdaq.
IPC The Hospitalist Company Inc. said Thursday that it has filed with the Securities and Exchange Commission for an initial public offering of common stock. The number of shares and offering price was not announced, but reports said that the company was hoping to raise about $105 million. The North Hollywood-based network of physicians said in a statement that it plans to trade on the ticker symbol IPCM on the New York Stock Exchange. Credit Suisse and Jefferies & Co. are serving as co-lead underwriters.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- CytRx Shares Holding Up Well Despite CFO Departures
- CytRx Spins Off Subsidiary
- RXi Pharmaceuticals Has Secondary Offering
- American Apparel, IPC, CytRx Among Week’s Big Movers
- CytRx Acquires Innovive Pharmaceuticals
- CytRx CFO Quits
- CytRx Creates Subsidiary for Gene-Silencing Technology
- CytRx Sells Remaining Stake in Spin-Off